News and Announcements
Dragonfly Biosciences ASX Listing Applications are now open
- Published December 08, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Finexia is pleased to advise that the Dragonfly Biosciences initial public offer (IPO) is now open and accepting applications from the public. The company is seeking raise A$10M with the aim of listing on the ASX in late December 2021.
Dragonfly Biosciences Ltd is a vertically integrated ‘seed-to-shelf’ cannabidiol (CBD) business that trades under the Dragonfly CBD brand. The Company owns the entire value chain from their certified organic farms, extraction facilities and state of the art laboratories used for producing premium CBD products.
Dragonfly CBD products have been voted “Best CBD Product” in 2020 by Boots UK, one of the world’s most respected health and beauty retailer and pharmacy chains. Dragonfly’s product distribution extends into national grocery and specialty chains including Tesco, Sanisbury’s and Amazon UK, securing their status as a market leader in the UK and beyond.
The Company is issuing 50M shares at A$0.20 through the IPO and intends to raise A$10M to be deployed for accelerated global expansion and further product development.
Applications close 5.00pm AEST 14 December 2021.
To be part of the exciting journey that is Dragonfly, please obtain a copy of the prospectus via the button below.
Download Replacement Prospectus
About the Company
Dragonfly Biosciences was incorporated on 29 June 2017 and is a premium retailer of cannabidiol (CBD) oil. Through its extensive research and development, Dragonfly controls the process from seed to sale, with the aim of producing the highest and most consistent product quality. Dragonfly currently offers a range of CBD health and lifestyle products.
Dragonfly aims to expand its business and product range in line with legislative changes in Europe, the USA and Australia. As demand grows for CBD health supplements, Dragonfly seeks to be the go-to producer and supplier of CBD for both businesses and consumers.
Dragonfly’s products are tested in third-party laboratories, as well as implementing its own testing regime to ensure consistency and quality across the board with Good Manufacturing Practices (GMP). Its product line is standardised to contain specific quantities of cannabinoids including, CBD, CBD-a and CBG.
Company Updates
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Reinventing the Condom: How an Australian Deep-Tech Startup Plans to Disrupt a $12 Billion Market
For more than half a century, the global condom industry has remained fundamentally unchanged, constrained by standard materials like latex and solid synthetic polymers. Despite widespread consumer demand for better alternatives, product design has treated the device strictly as a mechanical barrier, sacrificing feel for function. Sydney-based Eudaemon Technologies is setting out to upend that […]
Backed By Leading Investment Groups and Family Offices
